Testing Zasocitinib in Adults With Active Psoriatic Arthritis
Tests zasocitinib against placebo in adults with active psoriatic arthritis not yet treated with biologics.
Plain-language title generated from the registry record
Registry title: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Key facts
- Where
- New Taipei City, Taichung, Tainan, and Zhong Zheng Qu, TaiwanSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active psoriatic arthritis who have never taken biologic medicines. It tests how well zasocitinib works compared with placebo and an active comparator.
- Age
- 18 years or older (19 years or older in South Korea).
- Sex
- All sexes can join.
- Disease stage
- Active psoriatic arthritis with symptoms for at least 3 months, at least 3 tender and 3 swollen joints, and either 1 plaque psoriasis lesion of 2 cm (0.8 in) or more or nail changes typical of psoriasis.
- Earlier treatment
- Must not have taken biologic DMARDs before. Must have had an inadequate response to an NSAID (not required in the EU/EEA) or to a conventional DMARD.
Main reasons for not taking part
- Other diseases that could confuse the results, such as rheumatoid arthritis, axial spondyloarthritis, lupus, Lyme disease, gout or fibromyalgia
- Another skin condition that would interfere with the study assessments, such as non-plaque psoriasis
Read by machine on 9 November 2026.
Where in Taiwan
- Far Eastern Memorial Hospital | Allergy, Immunology and Rheumatology DepartmentNew Taipei City, TaiwanNo longer taking part
- Chung Shan Medical University HospitalTaichung, TaiwanNo longer taking part
- Chi Mei Medical CenterTainan, TaiwanNo longer taking part
- National Cheng Kung UniversityTainan, TaiwanNo longer taking part
- National Taiwan University HospitalZhong Zheng Qu, TaiwanNo longer taking part
Trial details
- Who runs it
- Takeda
- Trial code
- NCT06671483EU 2024-513111-27-00
- Record updated
- 12 November 2026
- Original description
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).Read full original descriptionShow less
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.
The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
Inclusion: Age:; The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is >=19 years of age; Disease Characteristics:; The participant has a diagnosis of PsA; The participant must have signs and symptoms of PsA for at least 3 months prior to screening; The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria); The participant has active arthritis as shown by a minimum of >=3 tender joints in TJC68 and >=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits; The participant has at least 1 active lesion of plaque PsO >=2 cm in diameter, or any nail or nail bed changes characteristic of PsO; Medications for PsA:; The participant has had at least one of the following:; Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID) (not applicable in the European Union [EU]/ European Economic Area [EEA]), OR; Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD).
Exclusion: The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO); The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia; PsA and PsO:.